FDA approves Sanofi's Tzield as first disease-modifying therapy for stage 3 type 1 diabetes in children.

The FDA has granted accelerated approval to Sanofi's Tzield (teplizumab-mzwv) for children aged 8 to 17 recently diagnosed with stage 3 type 1 diabetes (T1D). This is the first disease-modifying therapy aimed at delaying the decline of insulin production in these patients, based on positive results from the PROTECT phase 3 study involving over 900 patients. Tzield targets the autoimmune attack on insulin-producing beta cells, potentially changing the treatment approach for stage 3 T1D. Continued approval depends on further confirmatory studies, with ongoing trials like BETA-PRESERVE underway.